Skip to content
10-Q

Quarterly Report

NUTRA PHARMA CORP. NPHC

0001493152-26-000067

← back to feed
Filed
Jan 2, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2024 · Jan 2, 2026 7.1B sh
Long Term Debt Q3 2024 · Sep 30, 2024 $141.09K
Long Term Debt Q3 2024 · Dec 31, 2023 $143.66K
Short Term Investments Q3 2024 · Sep 30, 2024 $17.6K
Short Term Investments Q3 2024 · Dec 31, 2023 $35.2K
Cash And Equivalents Q3 2024 · Sep 30, 2024 $0
Cash And Equivalents Q3 2024 · Dec 31, 2023 $0
Current Liabilities Q3 2024 · Sep 30, 2024 $15.21M
Current Liabilities Q3 2024 · Dec 31, 2023 $14.17M
Total Liabilities Q3 2024 · Sep 30, 2024 $15.38M
Total Liabilities Q3 2024 · Dec 31, 2023 $14.41M
Current Assets Q3 2024 · Sep 30, 2024 $310.76K
Current Assets Q3 2024 · Dec 31, 2023 $314.06K
Total Assets Q3 2024 · Sep 30, 2024 $558.84K
Total Assets Q3 2024 · Dec 31, 2023 $640.4K
Shares Diluted Q3 2024 · Sep 30, 2023 7.61B sh
Shares Diluted Q3 2024 · Sep 30, 2023 7.6B sh
Operating Cash Flow Q3 2024 · Sep 30, 2023 −$363.81K
Stockholders Equity Q3 2024 · Sep 30, 2023 −$13.53M
Stockholders Equity Q3 2024 · Jun 30, 2023 −$13.25M
Stockholders Equity Q3 2024 · Dec 31, 2022 −$12.38M
Eps Diluted Q3 2024 · Sep 30, 2023 $0.00
Eps Diluted Q3 2024 · Sep 30, 2023 $0.00
Eps Basic Q3 2024 · Sep 30, 2023 $0.00
Eps Basic Q3 2024 · Sep 30, 2023 $0.00
Sga Expense Q3 2024 · Sep 30, 2023 $280.75K
Sga Expense Q3 2024 · Sep 30, 2023 $944.01K
Net Income Q3 2024 · Sep 30, 2023 −$278.49K
Net Income Q3 2024 · Sep 30, 2023 −$1.15M
Operating Income Q3 2024 · Sep 30, 2023 −$165.77K
Operating Income Q3 2024 · Sep 30, 2023 −$746.76K
Gross Profit Q3 2024 · Sep 30, 2023 $114.98K
Gross Profit Q3 2024 · Sep 30, 2023 $302.72K
Revenue Q3 2024 · Sep 30, 2023 $51.61K
Revenue Q3 2024 · Sep 30, 2023 $158.53K